The Michael J. Fox Foundation for Parkinson’s Research announced June 22 that it will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120.
The gene therapy product delivers the gene for neurturin, a neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. The company said in a news release that CERE-120 has the potential to improve motor function as well as slow Parkinson’s disease (PD) progression.
Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene Inc., said this is the company’s fourth award from The Michael J. Fox Foundation.
The principal investigators of this award are Ceregene Executive Vice President and Chief Scientific Officer Raymond T. Bartus, Ph.D., and Joao Siffert, M.D., Ceregene’s chief medical officer.
Patient enrollment for the new Phase 2 study is expected to begin later this summer at 10 major medical centers throughout the U.S.